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background: Sudden cardiac death (SCD) primary prevention guidelines advocate ICD-therapy in patients with reduced left ventricular ejection 
fraction (LVEF), but real-life data suggest that the benefit from ICD therapy for some patients may be lower than expected from controlled studies.
methods: Using registry data, 788 patients with reduced LVEF, who received ICD for primary SCD prevention during 2007-2011 in four tertiary 
care Swedish hospitals, were identified (age 64±11 y, 82% men, 62% ischemic ethiology, 45% CRT-D). The patients’ records were scrutinized for the 
presence of earlier suggested clinical risk factors (age>70, QRS duration>120ms, NYHA class III-IV, atrial fibrillation or S-creatinine>106 μmol/l), 
ICD discharge and survival. Mean follow-up was 39±18 months.
results: In 7% no risk factors (low-risk) were identified, 54% had 1-2 risk factors (medium-risk) and 39% had 3-5 risk factors (high-risk). Mean 
LVEF in the total population was 26±7%. Annual mortality was 6%, and increased significantly with risk factor group (p<0.001). In total, 157 patients 
(20%) died or had a heart transplant (see table). Neither appropriate nor inappropriate therapy differed between groups.
conclusion: Our data from a large real-life cohort contradicts earlier reported negligible benefit from ICD-implants in the low- and high-risk 
groups. Despite considerable mortality associated with higher risk score, similar ICD discharge rate across all three groups suggests similar SCD 
prevention benefit.
